Abstract: The present invention provides in one aspect novel fusion partner cells that ectopically express one or more genes that alter the phenotype of a hybrid cell made from a fusion of the fusion partner cell and a fusion cell, hybrid cell lines produced using the fusion partner cells. The invention in another aspect provides antibodies produced by certain hybrid cell lines, and compositions containing one or a combination of such antibodies or antigen-binding fragments thereof. The invention also provides in another aspect methods of using the antibodies or antigen-binding fragments thereof for diagnosis and treatment of diseases characterized by the antigens specifically bound by the antibodies.

Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.

Abstract: DNA encoding TGF-? type III receptor of mammalian origin, DNA encoding TGF-? type II receptor of mammalian origin, TGF-? type III receptor, TGF-? type II receptor and uses therefor.

Abstract: DNA encoding TGF-? type III receptor of mammalian origin, DNA encoding TGF-? type II receptor of mammalian origin, TGF-? type III receptor, TGF-? type II receptor and uses therefor.

Abstract: DNA encoding TGF-? type III receptor of mammalian origin, DNA encoding TGF-? type II receptor of mammalian origin, TGF-? type III receptor, TGF-? type II receptor and uses therefor.

Abstract: The invention relates to an orthotopic xenograft rodent model in which the stromal and epithelial components of the reconstructed mammary gland are of human origin, and to methods of making the mouse. The invention also relates to methods of using the rodent, including methods of identifying agents or drugs that inhibits abnormal growth of human breast epithelial cells or that inhibit the formation of breast tumors or other hyperplastic growths.

Abstract: The present invention provides a connector device or reconstitution device (10) for placing a first container (12), such as a liquid container (e.g. flexible container or syringe), in fluid communication with a second container (14), such as a drug vial. The connector device (10) has a first sleeve (32) having a first end (36) and a second end (38). The first sleeve (32) has at the first end (36), a first attaching member (30) adapted to attach to the liquid container (12). The connector device (10) also has a second sleeve (34) having a first end (48) and a second end (50). A second attaching member (28) is attached on the second end (50) of the second sleeve (34) and is adapted to attach to the second container (14). The second attaching member (28) has a sealing member (84). A piercing member (76) projects within the sleeves (32,34) for providing a fluid flow path from the first container (12) to the second container (14).

Abstract: Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. Also described is the determination of the difference between the rat neu oncogene and its corresponding proto-oncogene. Also described are nucleic acid probes reactive with regions of the proto-oncogene or oncogene, as are methods for their use in detecting the occurrence of the two types of genes. Antibodies specific for gene products encoded by the neu genes are also described, as are methods for their use.

Abstract: The present invention provides in one aspect novel fusion partner cells that ectopically express one or more genes that alter the phenotype of a hybrid cell made from a fusion of the fusion partner cell and a fusion cell, hybrid cell lines produced using the fusion partner cells. The invention in another aspect provides antibodies produced by certain hybrid cell lines, and compositions containing one or a combination of such antibodies or antigen-binding fragments thereof. The invention also provides in another aspect methods of using the antibodies or antigen-binding fragments thereof for diagnosis and treatment of diseases characterized by the antigens specifically bound by the antibodies.

Abstract: DNA encoding TGF-&bgr; TYPE III receptor of mammalian origin, DNA encoding TGF-&bgr; type II receptor of mammalian origin, TGF-&bgr; type III receptor, TGF-&bgr; type II receptor and uses therefor.

Abstract: DNA encoding TGF-.beta. TYPE III receptor of mammalian origin, DNA encoding TGF-.beta. type II receptor of mammalian origin, TGF-.beta. type III receptor. TGF-.beta. type II receptor and uses therefor.

Abstract: The mammalian TGF-.beta. type II receptor has been cloned. Recombinant TGF-.beta.-binding receptor polypeptides are useful to alter the binding of TGF-.beta. to its receptors and to modulate the effects of TGF-.beta. in vivo.

Abstract: The invention provides cDNAs encoding the human and rodent transforming growth factor-beta (TGF-.beta.) type III receptors. Nucleic acids encoding the mammalian receptors and soluble receptor polypeptides derived from them, expression systems for their production, and the polypeptides per se also provided.

Abstract: The mammalian TGF-.beta. type II receptor has been cloned. Nucleic acids encoding full-length and soluble receptor polypeptides, as well as fragments of such nucleic acids useful as probes, are provided. Corresponding vectors, transformed host cells, and their use to produce recombinant TGF-.beta. receptors are also described.

Abstract: The mammalian TGF-.beta. type II receptor has been cloned. Recombinant full-length and soluble receptor polypeptides, as well as TGF-.beta.-binding fragments of such polypeptides, are provided.

Abstract: This invention relates to a substantially purified p100 which is a human neu related protein having a molecular weight in the range from about 97,000 daltons to about 115,000 daltons which corresponds substantially to the extracellular domain of the human neu gene product, said protein being detectable in a biological fluid.In another embodiment this invention relates to assays for detecting this protein.Finally, this invention also concerns monoclonal antibodies which are capable of binding to p100.

Abstract: Experiments designed to define the differences between the pas p21 oncogene DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly.sup.12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, serological reagents, such as antibodies specific for either p21 protein expressed from the proto-oncogene or p21 expressed from the oncogene, or a common site therein, are described.

Abstract: A pet collar is disclosed which provides a great variety of length of adjustments wherein a strap has a buckle at one end and a connector at the other end. The connector is attachable to the outer surface of the strap at a variety of positions to retain the end against the strap.

Abstract: Oligonucleotide probes reactive with regions of neu oncogenes of mammalian origin in which the mutation causing activation of such oncogenes is contained are described, as are methods for their use in detecting the presence of neu oncogenes in tumor cells. Antibodies specific for gene products encoded by neu oncogenes are also described.

Abstract: Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly.sup.12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, seralogical reagents, such as antibody specific for either p21 protein expressed from the proto-oncogene or oncogene, or a common site therein, are described.